Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Valassis Communications, Inc., In the Matter of
Valassis, a leading producer of free-standing newspaper inserts in the United States, has settled charges that it violated Section 5 of the FTC Act by attempting to collude with News America Marketing, its only rival, to eliminate competition between the two companies. During a conference call with industry analysts, a Valassis executive invited NewsAmerica to join in a scheme to allocate customers and fix prices in order to end an ongoing price war between the two companies. Under the consent order settling the FTC’s complaint, Valassis is barred from engaging in or inviting collusive agreements with other publishers or attempting to collude with its competitors.
Procter & Gamble Company and The Gillette Company, In the Matter of
Allergan, Inc., and Inamed Corporation, In the Matter of
The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.
American Bartending Institute, Inc., et al.
Olson, Matthew, and Leroy, Jennifer
Optin Global, Inc., also d/b/a Vision Media Limited Corp. et al.
Health Care Alliance of Laredo, L.C., In the Matter of
Jumpstart Technologies, LLC, U.S. (for the FTC)
DSW Inc.,In the Matter of
Conversion Marketing, Inc., et al.
Teva Pharmaceutical Industries Ltd. and IVAX Corporation, In the Matter of
The consent order allowed Teva to acquire IVAX Corporation, provided the companies sell the rights and assets needed to manufacture and market 15 generic pharmaceutical products. Among the drugs sold were several forms of generic amoxicillin and amoxicillin clavulanate potassium that are widely used in the United States.